文献速递胸部肿瘤

Iza-bren(EGFR-HER3双特异性ADC)治疗EGFR突变NSCLC的I/II期汇总分析

Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials.
PubMed 文献 · Ann Oncol · 2026-01-27

该汇总分析纳入171例经EGFR TKI治疗进展的晚期EGFR突变NSCLC患者,评估Iza-bren的疗效与安全性。推荐II期剂量为2.5 mg/kg第1、8天每3周一次,确认客观缓解率47.4%,中位无进展生存期6.9个月,中位总生存期24.8个月,安全性可控。

要点

  • 经TKI进展的EGFR突变NSCLC中,Iza-bren确认ORR达47.4%,DCR达81.3%。
  • 推荐II期剂量下初治化疗后TKI进展患者ORR 56.0%,中位PFS 12.5个月。
  • 安全性以血液学毒性为主,间质性肺病罕见(0.6%,均为1级)。

核心结论

  • 在经重度治疗的EGFR突变NSCLC中,Iza-bren显示出有前景的抗肿瘤活性和可控的安全性。
  • 上述结果为探索性事后汇总分析,具有假设生成性质,正在随机试验中进一步评估。

研究设计与样本

  • 汇总I期剂量递增/扩展试验(BL-B01D1-101;NCT05194982)和II期多队列试验(BL-B01D1-203;NCT05880706)的个体患者数据。
  • 纳入171例经既往EGFR TKI治疗进展的晚期EGFR突变NSCLC患者,数据截止2025年6月30日,中位随访20.5个月。
  • 推荐II期剂量为2.5 mg/kg,第1天和第8天给药,每3周一次。

主要发现

  • 汇总人群中确认客观缓解率为47.4%(95%CI 39.7%–55.1%),疾病控制率为81.3%(95%CI 74.6%–86.8%)。
  • 中位缓解持续时间为8.5个月(95%CI 6.9–11.2个月),中位无进展生存期为6.9个月(95%CI 5.5–9.6个月),中位总生存期为24.8个月(95%CI 18.5个月–未达到)。
  • 推荐II期剂量组(n=121)疗效一致:确认客观缓解率48.8%,疾病控制率81.0%,中位无进展生存期6.9个月,中位总生存期24.8个月。
  • 推荐II期剂量下化疗初治、TKI进展患者(n=50)确认客观缓解率56.0%,疾病控制率90.0%,中位缓解持续时间13.7个月,中位无进展生存期12.5个月,中位总生存期未达到。
  • 治疗相关不良事件发生率98.8%(≥3级70.2%),以血液学毒性为主;间质性肺病罕见(0.6%,均为1级);因治疗相关不良事件停药1.2%;未报告治疗相关死亡。

临床怎么用

  • 对于经EGFR TKI治疗进展的EGFR突变NSCLC患者,Iza-bren可作为有前景的后线治疗选择,尤其化疗初治人群显示更高缓解率和更长无进展生存期。
  • 临床应用需重点监测血液学毒性,并警惕罕见的间质性肺病。

局限性

  • 为探索性事后汇总分析,结果具有假设生成性质,需随机试验进一步验证。
  • 原文未报告随机对照比较或预设统计检验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Therapeutic options after progression on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) remain limited for patients with EGFR-mutated non-small-cell lung cancer (NSCLC). Izalontamab brengitecan (Iza-bren; BL-B01D1) is a first-in-class bispecific antibody-drug conjugate targeting EGFR and human epidermal growth factor receptor 3 (HER3) with preclinical and early clinical activity. PATIENTS AND METHODS: We pooled individual patient data from a phase Ia/Ib dose-escalation/expansion trial (BL-B01D1-101; NCT05194982) and a phase II multicohort trial (BL-B01D1-203; NCT05880706) in patients with advanced EGFR-mutated NSCLC who had disease progression on prior EGFR TKI therapy. Key endpoints were confirmed objective response rate (cORR), disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. The recommended phase II dose (RP2D) was 2.5 mg/kg on days 1 and 8 every 3 weeks. RESULTS: A total of 171 patients were included (data cut-off 30 June 2025; median follow-up 20.5 months). In the pooled population, cORR was 47.4% [95% confidence interval (CI) 39.7% to 55.1%] and DCR was 81.3% (95% CI 74.6% to 86.8%); median DoR was 8.5 months (95% CI 6.9-11.2 months), median PFS was 6.9 months (95% CI 5.5-9.6 months), and median OS was 24.8 months (95% CI 18.5 months to not reached). Efficacy at the RP2D (n = 121) was consistent (cORR 48.8%; DCR 81.0%; median PFS 6.9 months; median OS 24.8 months). In chemotherapy-naive, post-TKI patients treated at the RP2D (n = 50), cORR was 56.0%, DCR was 90.0%, median DoR was 13.7 months, median PFS was 12.5 months, and median OS was not reached. Treatment-related adverse events occurred in 98.8% (grade ≥3: 70.2%), predominantly hematologic; interstitial lung disease was rare (0.6%, all grade 1). Discontinuation for treatment-related adverse events was 1.2%; no treatment-related deaths were reported. CONCLUSIONS: In this exploratory post hoc pooled analysis, Iza-bren demonstrated promising antitumor activity and a manageable safety profile in heavily pretreated EGFR-mutated NSCLC. These findings are hypothesis-generating and are being further evaluated in ongoing randomized trials.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Hong SD, Wang YS, Zhao HY, et al. Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials. Ann Oncol. 2026. PMID: 41611210. doi:10.1016/j.annonc.2026.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。